Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction
Authors:
- Elisa SchenaElisa Schena
- Elisabetta MattioliElisabetta Mattioli
- Chiara PeresChiara Peres
- Laura ZanottiLaura Zanotti
- Paolo MorselliPaolo Morselli
- Patricia IozzoPatricia Iozzo
- Maria Angela GuzzardiMaria Angela Guzzardi
- Chiara BernardiniChiara Bernardini
- Monica ForniMonica Forni
- Salvatore NesciSalvatore Nesci
- Massimiliano CaprioMassimiliano Caprio
- Carolina CecchettiCarolina Cecchetti
Open Access
Abstract
Type-2 Familial Partial Lipodystrophy (FPLD2), a rare lipodystrophy caused by LMNA mutations, is characterized by a loss of subcutaneous fat from the trunk and limbs and excess accumulation of adipose tissue in the neck and face. Several studies have reported that the mineralocorticoid receptor (MR) plays an essential role in adipose tissue differentiation and functionality. We previously showed that brown preadipocytes isolated from a FPLD2 patient’s neck aberrantly differentiate towards the white lineage. As this condition may be related to MR activation, we suspected altered MR dynamics in FPLD2. Despite cytoplasmic MR localization in control brown adipocytes, retention of MR was observed in FPLD2 brown adipocyte nuclei. Moreover, overexpression of wild-type or mutated prelamin A caused GFP-MR recruitment to the nuclear envelope in HEK293 cells, while drug-induced prelamin A co-localized with endogenous MR in human preadipocytes. Based on in silico analysis and in situ protein ligation assays, we could suggest an interaction between prelamin A and MR, which appears to be inhibited by mineralocorticoid receptor antagonism. Importantly, the MR antagonist spironolactone redirected FPLD2 preadipocyte differentiation towards the brown lineage, avoiding the formation of enlarged and dysmorphic lipid droplets. Finally, beneficial effects on brown adipose tissue activity were observed in an FPLD2 patient undergoing spironolactone treatment. These findings identify MR as a new lamin A interactor and a new player in lamin A-linked lipodystrophies.Keywords
Funding Information
- AIPROSAB (Prot. 3/2021 “TARGETS”, Prot. 3/2022 “PRE-RECEPTORS”, Prot. 20223WFJJ3)
- Italian MUR PRIN (Prot. 3/2021 “TARGETS”, Prot. 3/2022 “PRE-RECEPTORS”, Prot. 20223WFJJ3)
- IRCCS San Raffaele Institutional (Prot. 3/2021 “TARGETS”, Prot. 3/2022 “PRE-RECEPTORS”, Prot. 20223WFJJ3)
This publication has 55 references indexed in Scilit:
- Altered chromatin organization and SUN2 localization in mandibuloacral dysplasia are rescued by drug treatmentHistochemistry and Cell Biology, 2012
- Regulation of lipid stores and metabolism by lipophagyCell Death & Differentiation, 2012
- LMNA Mutations Induce a Non-Inflammatory Fibrosis and a Brown Fat-Like Dystrophy of Enlarged Cervical Adipose TissueThe American Journal of Pathology, 2011
- Reorganization of the nuclear lamina and cytoskeleton in adipogenesisHistochemistry and Cell Biology, 2011
- Perilipin Overexpression in White Adipose Tissue Induces a Brown Fat-Like PhenotypePLOS ONE, 2010
- The hsp90-FKBP52 Complex Links the Mineralocorticoid Receptor to Motor Proteins and Persists Bound to the Receptor in Early Nuclear EventsMolecular and Cellular Biology, 2010
- Identification and Importance of Brown Adipose Tissue in Adult HumansNew England Journal of Medicine, 2009
- Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-γ, and Proinflammatory AdipokinesCirculation, 2008
- Drugs affecting prelamin A processing: Effects on heterochromatin organizationExperimental Cell Research, 2008
- LMNA, encoding lamin A/C, is mutated in partial lipodystrophyNature Genetics, 2000